Skip to content

Frontiers in Psychiatry

ISSN 1664-0640

601 papers in the library · 9,228 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Frontiers in Psychiatry January 22, 2020 Earth Erowid, Fire Erowid, Albert Garcia‐romeu et al. 155 citations

While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Frontiers in Psychiatry January 21, 2020 Juan José Fuentes, Francina Fonseca, Matilde Elices et al. 176 citations

Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a...

DOI: 10.3389/fpsyt.2019.00943 (opens in new tab) Anxiety Addiction Randomized controlled trial Clinical trial +5

Characteristics of Adolescents Affected by Mass Psychogenic Illness Outbreaks in Schools in Nepal: A Case-Control Study.

Frontiers in Psychiatry 2020 Ram P Sapkota, Alain Brunet, Laurence J. Kirmayer 21 citations

This paper presents the first systematic case-control study of correlates of mass psychogenic illness (MPI) in an adolescent school population. MPI is generally construed as a dissociative phenomenon spread by social contagion to individuals who are prone to dissociation. We sought to test if the correlates of dissociative experiences most commonly proposed in the literature could predict...

DOI: 10.3389/fpsyt.2020.493094 (opens in new tab) Full text (opens in new tab) Nepal Childhood trauma Dissociation Emotional contagion +3

Graded Empathy: A Neuro-Phenomenological Hypothesis.

Frontiers in Psychiatry 2020 Jonathan Levy, Oren Bader 19 citations

The neuroscience of empathy has enormously expanded in the past two decades, thereby making instrumental progress for the understanding of neural substrates involved in affective and cognitive aspects of empathy. Yet, these conclusions have relied on ultrasimplified tasks resulting in the affective/cognitive dichotomy that was often modeled and overemphasized in pathological, developmental, and...

DOI: 10.3389/fpsyt.2020.554848 (opens in new tab) Full text (opens in new tab) Affective empathy Cognitive empathy Empathy dichotomy Intergroup conflicts +2

Quadratic Relationship Between Alexithymia and Interoceptive Accuracy, and Results From a Pilot Mindfulness Intervention.

Frontiers in Psychiatry 2020 Rachel V Aaron, Scott D. Blain, Matthew A. Snodgress et al.

Alexithymia, or a reduced ability to label and describe one's emotions, is a transdiagnostic construct associated with poor psychosocial outcomes. Currently, the mechanisms underlying affective deficits associated with alexithymia are unclear, hindering targeted treatment delivery. Recent research suggests deficient interoceptive awareness, or reduced awareness of one's internal bodily state,...

DOI: 10.3389/fpsyt.2020.00132 (opens in new tab) Full text (opens in new tab) Affect labeling Alexithymia Emotional awareness Emotional granularity +4

Repeated Nitrous Oxide Exposure Exerts Antidepressant-Like Effects Through Neuronal Nitric Oxide Synthase Activation in the Medial Prefrontal Cortex.

Frontiers in Psychiatry 2020 Wei Liu, Qian Li, Binglu Ye et al.

Clinical studies have demonstrated that exposure to the inhalational general anesthetic nitrous oxide (N2O) produces antidepressant effects in depressed patients. However, the mechanisms underlying the antidepressant effects of N2O remain largely unknown. Neuronal nitric oxide synthase (nNOS)-mediated nitric oxide (NO) synthesis is essential for brain function and underlies the molecular...

Modulation of Social Cognition via Hallucinogens and “Entactogens”

Frontiers in Psychiatry December 3, 2019 Katrin H. Preller, Franz X. Vollenweider 67 citations

Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have been shown to have the potential to modulate social processing. This article reviews...

DOI: 10.3389/fpsyt.2019.00881 (opens in new tab) Hallucinogen Social cognition Cognitive psychology

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

Frontiers in Psychiatry November 20, 2019 Laura Orsolini, Stefania Chiappini, Duccio Papanti et al. 41 citations

The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs. The psychopathological pattern of the "new psychoses" appears to be extremely different from the classical presentation. Therefore, clinicians need more data on...

DOI: 10.3389/fpsyt.2019.00851 (opens in new tab) Addiction Psychopathology Synthetic cannabinoids Perspective graphical +3

No Influence of Dopamine System Gene Variations on Acute Effects of MDMA

Frontiers in Psychiatry October 24, 2019 Patrick Vizeli, Matthias E. Liechti 9 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a recreational substance also investigated as medication for posttraumatic stress disorder. Dopamine (DA) system stimulation likely contributes to the acute mood effects of amphetamines, including MDMA. Genetic variants, such as single-nucleotide polymorphisms (SNPs), and polymorphic regions of the DA system genes may in part explain...

Treatment of Resistant Depression: A Pilot Study Assessing the Efficacy of a tDCS-Mindfulness Program Compared With a tDCS-Relaxation Program

Frontiers in Psychiatry October 23, 2019 Aurore Monnart, Marie-Anne Vanderhasselt, Elisa Schroder et al.

Background: This pilot study explores a therapeutic setting combining transcranial direct current stimulation (tDCS) and mindfulness-based cognitive therapy (MBCT) for patients with drug-resistant depression. tDCS has shown efficacy for depression treatment and improvement could be maintained with the combination with mindfulness, which has shown depression relapse-prevention...

DOI: 10.3389/fpsyt.2019.00730 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mindfulness-based cognitive therapy Rumination Cognitive control

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Frontiers in Psychiatry September 13, 2019 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 78 citations

Background: There is a growing interest in the use of psychedelic substances for health related purposes, including symptom relief for disorders like anxiety, depression, and pain. Although the focus of recent clinical trials has been on high doses of these substances, anecdotal evidence suggests that low (micro) doses are also effective, and may be more suitable for certain conditions....

DOI: 10.3389/fpsyt.2019.00672 (opens in new tab) Anxiety Mental health Depression economics Clinical psychology

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Frontiers in Psychiatry September 12, 2019 Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al. 172 citations

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...

DOI: 10.3389/fpsyt.2019.00650 (opens in new tab) MDMA Paroxetine Sertraline Psychotherapist

The Effects of Meditation, Yoga, and Mindfulness on Depression, Anxiety, and Stress in Tertiary Education Students: A Meta-Analysis

Frontiers in Psychiatry April 24, 2019 J. Breedvelt, Yagmur Amanvermez, Mathias Harrer et al.

Background: Meditation, yoga, and mindfulness are popular interventions at universities and tertiary education institutes to improve mental health. However, the effects on depression, anxiety, and stress are unclear. This study assessed the effectiveness of meditation, yoga, and mindfulness on symptoms of depression, anxiety, and stress in tertiary education students. Methods: We searched...

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy

Frontiers in Psychiatry March 20, 2019 Ben Sessa, David Nutt, Laurie Higbed 141 citations

This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA...

EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis

Frontiers in Psychiatry January 17, 2019 Santiago Castro-Zaballa, Matías Cavelli, Joaquín González et al.

Cognitive processes are carried out during wakefulness by means of extensive interactions between cortical and subcortical areas. In psychiatric conditions, such as psychosis, these processes are altered. Interestingly, REM sleep where most dreams occurs, shares electrophysiological, pharmacological, and neurochemical features with psychosis. Because of this fact, REM sleep is considered a...

Cutting-Edge Search for Safer Opioid Pain Relief: Retrospective Review of Salvinorin A and Its Analogs.

Frontiers in Psychiatry 2019 Jordan K Zjawiony, Antônio S Machado, Ricardo Menegatti et al. 18 citations

Over the years, pain has contributed to low life quality, poor health, and economic loss. Opioids are very effective analgesic drugs for treating mild, moderate, or severe pain. Therapeutic application of opioids has been limited by short and long-term side effects. These side effects and opioid-overuse crisis has intensified interest in the search for new molecular targets and drugs. The...

Severe Sleep Deprivation Causes Hallucinations and a Gradual Progression Toward Psychosis With Increasing Time Awake

Frontiers in Psychiatry July 10, 2018 Flavie Waters, Vivian Chiu, Amanda Atkinson et al. 163 citations

Background: Going without sleep for long periods of time can produce a range of experiences, including perceptual distortions and hallucinations. Many questions, however, remain unanswered regarding the types of symptoms which are most reliably elicited, the time of symptom onset, and whether symptoms worsen over time towards psychotic decompensation. Since sleep deprivation exceeding 48 h is...

DOI: 10.3389/fpsyt.2018.00303 (opens in new tab) Anxiety Sleep deprivation Audiology Psychosis +6

Fantasy Proneness Correlates With the Intensity of Near-Death Experience

Frontiers in Psychiatry June 7, 2018 Charlotte Martial, Héléna Cassol, Vanessa Charland-Verville et al. 70 citations

Little is known about the personality characteristics of those who have experienced a "Near-Death Experience" (NDE). One interesting candidate is fantasy proneness. We studied this trait in individuals who developed NDEs in the presence (i.e., classical NDEs) or absence (i.e., NDEs-like) of a life-threatening situation. We surveyed a total of 228 individuals. From those, 108 qualified as NDE...

Psychedelic Fauna for Psychonaut Hunters: A Mini-Review

Frontiers in Psychiatry May 22, 2018 Laura Orsolini, Michela Ciccarese, Duccio Papanti et al. 25 citations

Currently different classes of psychoactive substances are easily available for abuse, including several hundred novel psychoactive substances (NPS). Some of these drugs occur naturally in plants and animals or are chemically modified from plant or animal compounds and have been abused by humans over millennia. Recently, the occurrence of a new "drug culture" (e.g., psychonauts) who consume a...

Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol

Frontiers in Psychiatry May 14, 2018 Ben J Palanca, Hannah R. Maybrier, Angela M. Mickle et al. 16 citations

Electroconvulsive therapy (ECT) employs the elective induction of generalizes seizures as a potent treatment for severe psychiatric illness. As such, ECT provides an opportunity to rigorously study the recovery of consciousness, reconstitution of cognition, and electroencephalographic (EEG) activity following seizures. Fifteen patients with major depressive disorder refractory to pharmacologic...

Sexual Hallucinations in Schizophrenia Spectrum Disorders and Their Relation With Childhood Trauma

Frontiers in Psychiatry May 9, 2018 Jan Dirk Blom, Esmeralda Mangoenkarso 20 citations

Background: Sexual hallucinations are probably the most neglected types of hallucination, even in psychiatric settings. They are often multimodal in nature, and their prevalence rate is unknown. For other types of hallucination, notably auditory hallucinations, childhood trauma is an important risk factor. However, whether this also applies to sexual hallucinations is unknown. Objective: To...

Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls

Frontiers in Psychiatry May 8, 2018 Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Erick Allan Dos Santos Silva et al. 102 citations

Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect...

Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum

Frontiers in Psychiatry April 30, 2018 Michael Chary, David Yi, Alex F. Manini 32 citations

Novel psychoactive substances (NPS) refer to synthetic compounds or derivatives of more widely known substances of abuse that have emerged over the last two decades. Case reports suggest that users combine substances to achieve desired psychotropic experiences while reducing dysphoria and unpleasant somatic effects. However, the pattern of combining NPS has not been studied on a large scale....

DOI: 10.3389/fpsyt.2018.00135 (opens in new tab) MDMA Hallucinogen Synthetic cannabinoids Designer drug +1

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

Frontiers in Psychiatry April 24, 2018 Paulo César Ribeiro Barbosa, Luís Fernando Tófoli, Michael P. Bogenschutz et al. 95 citations

The aims of this study were to assess the impact of ceremonial use of ayahuasca-a psychedelic brew containing N,N-dimethyltryptamine (DMT) and β-carboline -and attendance at União do Vegetal (UDV) meetings on substance abuse; here we report the findings related to alcohol and tobacco use disorder. A total of 1,947 members of UDV 18+ years old were evaluated in terms of years of membership and...

DOI: 10.3389/fpsyt.2018.00136 (opens in new tab) Ayahuasca Attendance Environmental health Demography +1